Safety and efficacy of an enteroscopy-based approach in reducing the polyp burden in patients with Peutz–Jeghers syndrome: experience from a tertiary referral center

Pablo Cortegoso Valdivia, Emanuele Rondonotti and Marco Pennazio

Abstract

Background: Patients with Peutz–Jeghers syndrome develop hamartomatous polyps in the small bowel, possibly causing anemia, intussusception, and obstruction. We aimed to evaluate the impact of an enteroscopy-based approach, including both device-assisted and intraoperative enteroscopy, on the reduction of the polyp burden in a cohort of adult Peutz–Jeghers syndrome patients.

Materials and methods: A retrospective study was conducted at Azienda Ospedaliero-Universitaria Città della Salute e della Scienza in Turin, Italy. Consecutive Peutz–Jeghers syndrome patients eligible for device-assisted or intraoperative enteroscopy, between January 2003 and November 2019, were included. Enteroscopy technical issues and complications were recorded. At the time of index enteroscopy, the patients’ clinical records were retrospectively reviewed, and clinical data were recorded until November 2019.

Results: Overall, 24 patients were included. Before inclusion, 16/24 patients (66.7%) underwent small bowel surgery for polyp-related complications, 13 of which (81.2%) in an emergent setting. Two patients had a history of small bowel neoplasms. During the timeframe, 47 device-assisted enteroscopies and 9 intraoperative enteroscopies were performed, and 247 small bowel polyps were endoscopically removed. The overall complication rate was 12.8% (8.5% for device-assisted enteroscopy, 22.2% for intraoperative enteroscopy). The median observation time was 108 months: in this timeframe, two patients developed small bowel polyp-related complications requiring emergent surgery. No patients developed small bowel cancer, but nine extra-gastrointestinal neoplasms were recorded.

Conclusion: An enteroscopy-based approach appears to be well tolerated and effective in decreasing polyp-related complications in Peutz–Jeghers syndrome patients, thus reducing the need for emergent surgery. Although the prevention of small bowel polyp-related complications remains the main goal in these patients, the high incidence of extra-gastrointestinal neoplasms appears to be a rising issue.

Keywords: device-assisted enteroscopy, enteroscopy, Peutz–Jeghers syndrome, small bowel
highest incidence with a cumulative risk of 33%
at the age of 60, mainly occurring in the colon
and in the small bowel (SB).\textsuperscript{5} Breast and pancreatic cancers are the most frequent extra-GI neoplasms in PJS patients.

PJS hamartomatous polyps can occur anywhere in
the GI tract, but they are most commonly located
in the small intestine; up to 96% of PJS patients
develop nondysplastic hamartomatous polyps
in the SB, while about one-third of them have gastric
or colonic polyps.\textsuperscript{6} SB PJS polyps usually arise
during childhood and the first complications, such
as intussusception, intestinal obstruction, or bleeding,
typically occur within the second decade.\textsuperscript{7,8} Moreover, as demonstrated in historical cohorts,
more than two-thirds of the patients underwent surgery because of SB polyp-related complications
by the end of the second decade.\textsuperscript{9,10}

Screening strategies aimed at reducing SB polyp-
related complications have evolved during the
years. The latest European guidelines suggest to
start the screening at the age of 8 years and to
repeat diagnostic procedures every 1–3 years
according to the clinical phenotype: video capsule
endoscopy (VCE) and magnetic resonance enter-
ography (MRE) are the recommended imaging
techniques for the study of the SB,\textsuperscript{7,11,12} Computed
tomography enterography (CTE) can also be used
to detect SB polyps, especially when $\geq 1$ cm.\textsuperscript{13} The
effectiveness of the dedicated SB diagnostic tools,
along with the widespread adoption of the recom-
mended screening policy, has resulted in an
increase in PJS patients needing polyp removal.
Until recently, the management of polyps of the
SB was mainly surgical, often requiring several
interventions over time with multiple resections,
potentially resulting in short bowel syndrome.
However, the development in recent years of
device-assisted enteroscopy (DAE) systems,
coupling an extensive evaluation of the SB with endo-
sopic polyp removal, has offered the opportunity
for a nonsurgical management of SB polyps. In
fact, recent guidelines agree that polypectomy or
endoscopic mucosal resection (EMR) by means of
DAE, or intraoperative enteroscopy (IOE) in
selected cases, is the most effective treatment for
the reduction of SB polyp burden in PJS patients
(Figure 1).\textsuperscript{11,14} However, although recent studies
on the endoscopic management of PJS patients
seem to provide consistent results, they include a
limited number of patients, are often focused on
the pediatric patients, and mostly have a short
follow-up (Table 1).\textsuperscript{8,15–31}

In this study, we aimed to assess the impact of
an enteroscopy-based approach (including both
DAE and IOE) on the reduction of the polyp bur-
den in a cohort of PJS patients.

**Methods**

All consecutive adult patients ($\geq 18$ years old)
with clinical or genetic diagnosis of PJS who
underwent DAE or IOE between January 2003
and November 2019, in a tertiary care center
(Azienda Ospedaliero-Universitaria Città della
Salute e della Scienza di Torino, Turin, Italy),
were included. This center has a well-established
dedicated pathway for diagnosis and therapy of
PJS patients and, since the introduction of DAE in
2003, taking into account the limitation of diag-
nostic procedures in locating the SB polyps, all the
Table 1. Literature.

| References          | No. of patients | No. of procedures | Observation time (months) | SBE (oral/anal) | DBE (oral/anal) | IOE | No. of polypectomies | Size of resected polyps | Maximum polyp size | No. of complications (%) |
|---------------------|----------------|------------------|---------------------------|----------------|----------------|-----|---------------------|------------------------|-----------------|-------------------------|
| Ohmiya and colleagues<sup>15</sup> | 2              | 5                | NA                        | –              | Oral [2]; anal [3] | –   | 18                  | >10 mm                 | 60 mm           | 1 fever, 1 abdominal pain [40%] |
| Plum and colleagues<sup>16</sup>     | 16             | 47               | NA                        | –              | Oral [39]; anal [8] | –   | 47                  | >15 mm                 | 50 mm           | 2 bleeding, 1 perforation, 1 propofol desaturation [8.5%] |
| Ohmiya and colleagues<sup>17</sup> | 18             | 80               | 54.0 (median)            | –              | Oral [42]; anal [38] | –   | 387                 | >5 mm                  | 50 mm           | 1 perforation, 1 pancreatitis, 1 postpolypectomy syndrome [3.8%] |
| Gao and colleagues<sup>19</sup>    | 13             | 29               | 19.0 (median)           | –              | Oral [26]; anal [3]  | –   | 79                  | >10 mm                 | 50 mm           | 0 (0%)                  |
| Kopáčová and colleagues<sup>19</sup> | 10            | 21               | NA                        | –              | Oral [14]; anal [0]  | 7   | 205                 | All polyps            | 60 mm           | 1 bleeding [4.8%]        |
| Sakamoto and colleagues<sup>15</sup> | 15            | 88               | 29.9 (mean)             | –              | 88 [NA]          | –   | 341                 | NA                    | NA             | 2 pancreatitis, 2 late bleeding, 1 perforation [5.7%] |
| Chen and colleagues<sup>21</sup>  | 6              | 17               | 32.0 (mean)             | 5 [NA]        | 12 [NA]         | –   | NA                  | >10 mm                 | 60 mm           | 0 (0%)                  |
| Akarsu and colleagues<sup>9</sup>  | 7              | 31               | NA                        | –              | Oral [21]; anal [9]  | 1   | 110                 | >10 mm                 | 100 mm          | 1 bleeding [3.2%]        |
| Gorospe and colleagues<sup>22</sup> | 22             | 34               | 27.0 (mean)             | –              | Oral [20]; anal [14] | –   | >10 mm              | 50 mm                  |                 | 2 abdominal pain, 1 intraprocedural bleeding, 1 self-limiting postprocedural bleeding [11.8%] |
| Serrano and colleagues<sup>23</sup> | 25             | 46               | 56.5 (median)           | –              | Oral [44]; anal [2]  | –   | 214                 | >10 mm                 | 40 mm           | 2 postprocedural bleeding, 1 perforation [6.5%] |
| Bizzarri and colleagues<sup>24</sup> | 10             | 23               | NA                        | Oral [16]; anal [7] | –              | –   | 53                  | >15 mm                 | NA             | 3 abdominal pain, 1 perforation [17.4%] |
| Torroni<sup>25</sup>          | 7              | 7                | NA                        | Oral [7]; anal [8] | –              | –   | 24                  | >15 mm                 | 50 mm           | 0 (0%)                  |
| Kröner and colleagues<sup>26</sup> | 2              | 2                | NA                        | –              | Oral [2]; anal [0]  | –   | 2                   | >20 mm                 | 25 mm           | 0 (0%)                  |
| Belsha and colleagues<sup>27</sup> | 16             | 22               | 26.0 (median)           | –              | Oral [11]; anal [8]  | 3   | 45                  | NA                    | NA             | 1 pelvic abscess [4.5%]  |
| Blanco-Velasco and colleagues<sup>28</sup> | 4             | 12               | NA                        | Oral [5]; anal [2] | Oral [3]; anal [2]  | –   | 35                  | >10 mm                 | 40 mm           | 1 pancreatitis [8.3%]    |
| Wang and colleagues<sup>29</sup>  | 97             | 320              | 46.7 (median)           | –              | Oral [185]; anal [135] | –   | 1661                | NA                    | NA             | 8 postprocedural bleeding, 4 perforation, 1 intussusception, 1 postpolypectomy syndrome [4.4%] |
| Perrod and colleagues<sup>30</sup> | 25             | 54<sup>a</sup>   | 60.0 (median)           | –              | Oral [25]; anal [8]  | 4   | 274                 | >10 mm                 | 60 mm           | 2 postprocedural bleeding, 1 perforation [5.5%] |
| Kirakosyan and Lokhmatov<sup>31</sup> | 30             | 30               | NA                        | 30 [NA]       | –              | –   | 68                  | >10 mm                 | NA             | 1 postprocedural perforation [3.3%] |

DBE, double-balloon enteroscopy; IOE, intraoperative enteroscopy; NA, not applicable; PE, push enteroscopy; SBE, single-balloon enteroscopy; –, not performed.

<sup>a</sup>Patients with all hamartomatous polyposis syndromes.

<sup>b</sup>Includes 2 PE and 15 spiral enteroscopies.
endoscopic procedures were performed by DAE or IOE, whereas push enteroscopies were no longer performed. In this center, patients were considered eligible for DAE or IOE if $\geq 1$ SB polyp $\geq 1.5$ cm in size was detected by diagnostic procedures (e.g. VCE, MRE, CTE, and SB series/enteroclysis). The route of insertion was decided depending on the imaging findings: when necessary, the patients underwent a combined approach (i.e. antegrade procedure followed by retrograde procedure some days after) in order to remove all the detected polyps. The choice between DAE and IOE was taken on a case-by-case basis, taking into account not only diagnostic test results (namely, number, size, and location of polyps) but also the characteristics of the patient, ongoing comorbidities, the previous history of surgical resection, the risk of short bowel, and the will of the patient. In case of possible IOE, we discussed the case during multidisciplinary meeting with radiologists, anesthesiologists, and surgeons.

For each included patient, the following data were collected through a dedicated database: patient’s characteristics at time of index enteroscopy (e.g. demographics, diagnostic SB procedures performed before enteroscopy, previous oncological history, history of GI surgical interventions, etc.), enteroscopic procedures performed during the study timeframe (e.g. type of procedure, procedural issues, complications, etc.), as well as any other clinically relevant event occurring during the study timeframe (e.g. surgical interventions, results of screening tests, etc.). These data were retrieved by checking hospital medical records and procedures’ reports or, when unavailable, by phone contact with the patients at time of data collection (i.e. November 2019). In our study, the observation time was defined as the time interval between the index enteroscopy (either DAE or IOE) and the data collection time.

All enteroscopic procedures were performed under deep sedation or under general anesthesia with tracheal intubation on a case-by-case basis, by a gastroenterologist experienced in enteroscopy (M.P., P.C.V.) after obtaining a written medical informed consent. As far as DAE is concerned, the insertion route was based on the location of the largest polyp at previous imaging.

DAE was performed with either single- or double-balloon system: the choice between single-balloon enteroscopy (SBE) and double-balloon enteroscopy (DBE) was related to the availability of the equipment at the time of the examination. SBE was performed with either a standard Olympus SIF-Q180 (Olympus Optical Co., Tokyo, Japan) or a prototype, equipped with a wider operative channel (3.2 mm). DBE was performed with Fujinon EN-450P5 or Fujinon EN-580T (Fujifilm Inc., Tokyo, Japan). Both systems are described in detail elsewhere. IOE was performed with Olympus SIF-100, SIF-Q140, or SIF-Q180 (Olympus Optical Co.); after surgical enterotomy, the progression in the SB loops was performed directly by the surgeon.

All polyps were resected endoscopically, with the en bloc or piecemeal technique according to the polyp size, morphology, and location. Submucosal injection prior to the polyp removal was performed with saline solution or diluted epinephrine (epinephrine ratio was at the discretion of the endoscopist). Prophylactic clipping after the polyp removal was done at the discretion of the endoscopist.

For IOE, surgically related complications were also collected and systematically recorded. Enteroscopy-related complications (e.g. bleeding, perforation, and acute pancreatitis) were systematically recorded: these were defined as intraprocedural when occurring during the procedure, early, or delayed when occurring within or over 24 h after the procedure, respectively. Bleeding was classified as minor when self-limiting or when hemostasis was achieved with endotherapy during the same procedure with a hemoglobin drop $< 2$ g/dL, and as major when a hemoglobin drop $\geq 2$ g/dL was observed or when transfusions were required or when further procedures were planned (i.e. embolization or a new DAE) to perform hemostasis or when it increased the length of the hospital stay. The diagnosis of acute pancreatitis was made according to the established diagnostic criteria. For IOE, surgically related complications were also collected and systematically recorded.

Results

Patients’ characteristics at time of index enteroscopy

Between January 2003 and November 2019, 24 patients who met the inclusion criteria were included; 15 of them were male (62.5%). At time of inclusion in this study, the median age was
The median time of observation was 108.0 months (IQR: 35.5–163.7). During this timeframe, 2/22 patients (9.1%) developed polyp-related complications (intussusception in both cases) which led to emergent surgery. No SB neoplasms were reported, whereas in 8/22 patients (36.4%) 9 extra-GI neoplasms were recorded: pancreatic cancer (n = 1), lung cancer (n = 2), breast cancer (n = 2), ovarian cancer (n = 1), papillary thyroid cancer (n = 1), basal cell carcinoma (n = 1), and hepatocellular carcinoma (n = 1). Out of 22 patients, 3 died during the observation period (13.6%): all deaths were directly related to extra-GI neoplasms (lung, pancreatic, and ovarian cancers).

**Discussion**
In our series, during a 17-year timeframe, we included 24 adult patients who underwent 56
### Table 2. Summary of cases.

| Patient | Evaluation at time of index DAE/IOE | Enteroscopic procedures during the study timeframe | Resected polyps: location (number) [dimension range] | Complications (no.) |
|---------|------------------------------------|--------------------------------------------------|-------------------------------------------------|---------------------|
|         | Age at enteroscopy | SB diagnostic procedure | Observation time (months) | SBE (oral/anal) | DBE (oral/anal) | IOE | DAE related | IOE related |
|---------|------------------|------------------------|---------------------------|----------------|----------------|-----|-------------|-------------|
| P.F.    | 45 y             | – – – –                | 46                        | Oral (1); anal (0) | –              | –   | Jejunum [2][15–20 mm] | Minor intraprocedural bleeding (1) |
| P.P.    | 25 y             | – – – –                | 124                       | Oral (3); anal (2) | –              | 1   | Duodenum [2]; jejunum [38]; ileum [12][5–60 mm] | Late perforation after IOE (1) |
| P.R.    | 21 y             | – – – –                | 170                       | Oral (1); anal (0) | Oral (1); anal (1) | 1   | Jejunum [9][10–40 mm] |
| P.N.    | 19 y             | – – – –                | 162                       | Oral (0); anal (1) | –              | 1   | Jejunum [4]; ileum [2][15–50 mm] |
| T.L.    | 39 y             | – – – –                | 77                        | –              | –              | 1   | Duodenum [0]a |
| M.N.    | 52 y             | – – – –                | 121                       | Oral (1); anal (1) | –              | 1   | Duodenum [2]; jejunum [3][30–40 mm] |
| G.L.    | 33 y             | – – – –                | 157                       | Oral (3); anal (1) | Oral (1); anal (1) | –   | Duodenum [1]; jejunum [9]; ileum [4][5–30 mm] |
| F.S.    | 32 y             | – – – –                | 167                       | Oral (1); anal (1) | Oral (1); anal (0) | –   | Duodenum [3]; jejunum [3][10–40 mm] |
| A.A.    | 25 y             | – – – b                | –                         | Oral (1); anal (0) | –              | –   | Jejunum [2][5–10 mm] |
| S.R.    | 43 y             | – – –                  | 73                        | Oral (2); anal (0) | –              | –   | Duodenum [1]; jejunum [1][10–50 mm] |
| M.A.    | 31 y             | – – –                  | 21                        | Oral (1); anal (0) | –              | –   | Jejunum [3][25–40 mm] | Minor intraprocedural bleeding (1) |
| C.M.    | 29 y             | – – –                  | 34                        | Oral (2); anal (0) | –              | –   | Jejunum [3]; ileum [1][5–40 mm] |

(Continued)
| Patient | Evaluation at time of index DAE/IOE | Enteroscopic procedures during the study timeframe |
|---------|--------------------------------------|--------------------------------------------------|
|         | Age at | SB diagnostic procedure | Observation time | SBE (oral/anal) | DBE (oral/anal) | IOE | Resected polyps: location | Complications (no.) |
|         | enteroscopy | VCE MRE CTE SB series | (months) | | | | (number) [dimension range] | DAE related | IOE related |
| P.G.   | 21 y   | y y - - | 16 | Oral (1); anal (0) | - | - | Duodenum (1); jejunum (3) [40-50 mm] |
| G.V.   | 20 y   | y y - - | 18 | Oral (1); anal (0) | - | - | Jejunum [3] [10-60 mm] |
| S.G.   | 54 y   | - - - y | 197 | - | - | 1 | Duodenum [1]; jejunum [2]; ileum [3] [5-10 mm] |
| S.A.   | 34 y   | - - y | - | Oral (2); anal (0) | - | - | Duodenum [2]; jejunum [17]; ileum [13] [5-40 mm] |
| D.D.   | 30 y   | - - - | 163 | Oral (2); anal (0) | Oral (2); anal (0) | 1 | Duodenum [32]; jejunum (1); ileum [15] [5-40 mm] | Minor intraprocedural bleeding (1) |
| P.R.   | 42 y   | - - y | 173 | Oral (3); anal (2) | Oral (1); anal (1) | 1 | Jejunum [10]; ileum [26] [10-50 mm] | Intraprocedural pneumothorax (1) |
| S.A.   | 51 y   | - - - | 164 | Oral (1); anal (0) | - | - | Jejunum [11] [10 mm] |
| S.A.   | 46 y   | - - - | 195 | - | - | 1 | Jejunum [4]; ileum [2] [10-50 mm] |
| R.A.   | 25 y   | y - y | 7 | Oral (1); anal (0) | - | - | Ileum [11] [15 mm] |
| M.A.   | 41 y   | - - - | 95 | Oral (2); anal (1) | - | - | Jejunum [4]; ileum [2] [10-35 mm] |
| P.G.   | 37 y   | y - y | 40 | Oral (1); anal (0) | - | - | Jejunum [11] [20 mm] |
| C.L.   | 65 y   | - - y | 31 | Oral (1); anal (0) | - | - | Duodenum [3]; jejunum [4] [10-45 mm] | Minor intraprocedural bleeding (1) |

CTE, computed tomography enterography; DAE, device-assisted enteroscopy; DBE, double-balloon enteroscopy; IOE, intraoperative enteroscopy; MRE, magnetic resonance enterography; SB, small bowel; SBE, single-balloon enteroscopy; VCE, video capsule enteroscopy.

Polyp not removable by enterotomy [descending duodenum, medial wall, size] and the patient underwent elective duodenopancreatectomy.

Not possible to retrieve data.
enteroscopic procedures overall (46 DAE and 9 IOE). For each included patient, we systematically collected the technical data of all the procedures, thus confirming the high efficacy and safety profile of the enteroscopy-based approach. For the majority of the patients, it was possible to collect clinical data during the study timeframe, which highlighted a reduction in SB polyp-related complications and an increase in extra-GI neoplasms.

As our study timeframe is long (about 17 years), we could observe the distribution of enteroscopic procedures over time. In detail, we observed a stable increase in device-assisted procedures throughout the years, whereas intraoperative procedures decreased progressively. In our study, the choice between DAE and IOE was not standardized: upfront IOE was considered after multidisciplinary discussion on a case-by-case basis, given its high rate of complications, when large or multiple polyps were detected during baseline imaging workup; no predefined cutoff for the polyp size or number was set to take IOE into consideration, but indeed an evaluation combining clinical and technical parameters, as well as the will of the patient, was performed. IOE was also indicated when polyps were considered too difficult to remove endoscopically. Nevertheless, all our data show that DAE has almost totally replaced IOE and that it is, by now, the reference standard technique for the removal of SB polyps in PJS patients.11

Although the patients were included in the study with different timings, at the time of index enteroscopy, in our case series the median time of observation was long (about 9 years). Interestingly, during this timeframe, there were only 2 cases of SB polyp-related complications with consequent

**Table 3.** Patients’ characteristics at time of inclusion.

| Demographics |  |
|---|---|
| No. of patients | 24 |
| Males, n (%) | 15 (62.5) |
| Median age (IQR) | 33.5 [25.0–43.5] |
| History of SB surgery |  |
| n (%) | 16 (66.7) |
| In emergency, n (%) | 13/16 (81.2) |
| History of SB neoplasms, n (%) | 2 (8.3) |
| History of extra-GI neoplasms, n (%) | 0 (0) |

GI, gastrointestinal; IQR, interquartile range; SB, small bowel.

**Figure 2.** Time trend of IOE and DAE.

DAE, device-assisted enteroscopy; IOE, intraoperative enteroscopy.

The dashed line shows the linear trend of DAE procedures over time, whereas the dotted line refers to the linear time trend of IOE.
emergent surgery: conversely, about two-thirds of these patients had a positive history for SB surgery due to polyp-related complications prior to joining the study. These data indirectly highlight the efficacy of enteroscopy in the management of SB polyps and appear to confirm the results of other studies in which, in patients undergoing multiple DAE sessions, the median number and dimension of resected SB polyps progressively decreased.20,29

Of note, during the observation period, no SB neoplasms were detected even though two patients had a positive history for SB cancer: although our cohort is small, it is intriguing to hypothesize a direct effect in SB cancer prevention in these patients, as suggested by Latchford and colleagues.34

In PJS patients, the endoscopic management of polyps is technically challenging due to their localization in the SB: the SB wall is thin, the working space is limited, and, sometimes, it is difficult to maintain a stable position with the scope. The complication rate of DAE in our study is relatively high (8.5%), especially when compared with studies with a large population of patients undergoing operative DAE.35 Nevertheless, it should be noted that these series take into account all operative enteroscopies, including hemostatic procedures which are generally less risky. Conversely, our data are exclusively related to polypectomy, which is considered to be the most dangerous procedure due to the thin SB wall, and they appear to be in line with the complication rate reported in similar case series of PJS patients undergoing DAE. Of note, most of the complications in our study were minor and were easily managed by the endoscopist during the same procedure.

On the contrary, the safety profile of IOE is different: although in line with the literature data, in our study IOE’s complication rate is higher than that of DAE. Possible explanations may be related to the higher number of polypectomies performed during IOE (median number of polyps removed during DAE and IOE being 2 and 7, respectively), to the localization of polyps and to their size (patients undergoing IOE were considered having more ‘difficult’ polyps), and to the surgical setting per se.
Interesting data came out of the oncological analysis: during the 9-year median observation period, eight patients developed nine extra-GI neoplasms, whereas at the time of inclusion in our network none of them had such a diagnosis. Moreover, extra-GI neoplasms are the cause of all deaths in our cohort. Although the median age at index enteroscopy was 35 years and both the study timeframe and the median observation time (17 and 9 years, respectively) were relatively long, in our opinion the trend observed in our cohort might not be due to aging only, but it is likely to reflect a true increase in extra-GI neoplasm incidence. Recent guidelines propose a dedicated multiorgan screening protocol for oncological prevention, which is also applied in our center.13 The evidence of surveillance recommendations is low, due to the rarity of the syndrome: the variety of the pathways of genetic mutations makes the understanding of cancer development in PJS patients extremely problematic.7,36,37 Currently, the rising incidence of extra-GI neoplasms appears to be the most significant burden for patients affected by PJS. Due to these data, it seems that ongoing cancer surveillance protocols are not sufficient yet.

Our study has several limitations. First of all, it is a descriptive study with a retrospective design. Second, although the study timeframe is wide, the overall number of included patients is relatively small; however, our sample size is in line with that reported in previous paper and the rarity of the syndrome, as well as the relative novelty of the DAE approach, compared with previous management strategies, makes the patient collection difficult. Third, as the main goal of enteroscopy examinations was to remove the polyp/s identified during previous diagnostic procedures (either VCE or SB dedicated cross-sectional imaging techniques), we did not attempt to perform complete SB explorations. Moreover, we are not able to estimate the impact of enteroscopy techniques taking into account the whole SB detection rate. However, we can hypothesize that the impact of a complete evaluation of the SB could be even higher than that observed in our study. Last but not least, some patients were referred to our tertiary care center by other small hospitals in Italy, and therefore we cannot be sure that the oncological extra-GI screening had been carried out properly (some patients could already harbor extra-GI lesions when they came to our attention) or that some other relevant data had been missed or not reported. Despite these limitations, we believe that these data might be one of the resources for establishing management strategies in patients with PJS in the future.

Conclusion
Results of our study show that the enteroscopy-based approach appears to be effective in decreasing polyp-related complications, thus reducing the need for emergent surgery, with an acceptable rate of procedural adverse events, particularly as far as DAE is concerned. Although the prevention of SB polyp-related complications remains the main goal of screening programs in PJS patients, the high incidence of extra-GI neoplasms is a rising issue in PJS patients.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

ORCID iDs
Pablo Cortegoso Valdivia https://orcid.org/0000-0002-8793-5890
Marco Pennazio https://orcid.org/0000-0001-6151-0395

References
1. Giardiello FM and Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 2006; 4: 408–415.
2. Peutz J. Very remarkable case of familial polyposis of mucous membrane of intestinal tract and nasopharynx accompanied by peculiar pigmentation of skin and mucous membrane. Nederl Maandschr Geneesk 1921; 10: 134–146.
3. Jeghers H, McKusick VA and Katz KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits: a syndrome of diagnostic significance. N Engl J Med 1949; 241: 993, illust; passim.
4. Jeghers H, McKusick VA and Katz KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits: a syndrome of diagnostic significance. N Engl J Med 1949; 241: 1031–1036.
5. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. *Clin Cancer Res* 2006; 12:3209–3215.

6. Schreiberman IR, Baker M, Amos C, et al. The hamartomatous polyposis syndromes: a clinical and molecular review. *Am J Gastroenterol* 2005; 100: 476–490.

7. Beggs AD, Latchford AR, Vasen HFA, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. *Gut* 2010; 59: 975–986.

8. Gupta A, Postgate AJ, Burling D, et al. A prospective study of MR enterography versus capsule endoscopy for the surveillance of adult patients with Peutz-Jeghers syndrome. *Am J Gastroenterol* 2010; 105: 594–599.

9. van Lier MG, Mathus-Vliegen EM, Wagner A, et al. High cumulative risk of intussusception in patients with Peutz-Jeghers syndrome: time to update surveillance guidelines? *Am J Gastroenterol* 2011; 106: 940–945.

10. Hinds R, Philip C, Hyer W, et al. Complications of childhood Peutz-Jeghers syndrome: implications for pediatric screening. *J Pediatr Gastroenterol Nutr* 2004; 39: 219–220.

11. van Leerdam ME, Roos VH, van Hout JF, et al. Endoscopic management of polyposis syndromes: European Society of Gastrointestinal Endoscopy (ESGE) guideline. *Endoscopy* 2019; 51: 877–895.

12. Gupta A, Postgate AJ, Burling D, et al. Double-balloon enteroscopy in patients with Peutz-Jeghers syndrome. *Endosc Gastrointest Ther* 2012; 23: 496–502.

13. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol* 2015; 110: 223–262.

14. Latchford AR and Phillips RK. Gastrointestinal polyposis and cancer in Peutz-Jeghers syndrome: clinical aspects. *Fam Cancer* 2011; 10: 455–461.

15. Ohmiya N, Taguchi A, Shirai K, et al. Endoscopic resection of Peutz-Jeghers polyposis throughout the small intestine at double-balloon endoscopy without laparotomy. *Gastrointest Endosc* 2005; 61: 140–147.

16. Plum N, May AD, Manner H, et al. Peutz-Jeghers syndrome: endoscopic detection and treatment of small bowel polyps by double-balloon enteroscopy. *Z Gastroenterol* 2007; 45: 1049–1055.

17. Ohmiya N, Nakamura M, Takenaka H, et al. Management of small-bowel polyps in Peutz-Jeghers syndrome by using enteroclysis, double-balloon enteroscopy, and videocapsule endoscopy. *Gastrointest Endosc* 2010; 72: 1209–1216.

18. Gao H, van Lier MG, Poley JW, et al. Endoscopic therapy of small-bowel polyps by double-balloon enteroscopy in patients with Peutz-Jeghers syndrome. *Gastrointest Endosc* 2010; 71: 768–773.

19. Kopáčová M, Bures J, Ferko A, et al. Comparison of intraoperative enteroscopy and double-balloon enteroscopy for the diagnosis and treatment of Peutz-Jeghers syndrome. *Surg Endosc* 2010; 24: 1904–1910.

20. Sakamoto H, Yamamoto H, Hayashi Y, et al. Nonsurgical management of small-bowel polyps in Peutz-Jeghers syndrome with extensive polypectomy by using double-balloon endoscopy. *Gastrointest Endosc* 2011; 74: 328–333.

21. Chen TH, Lin WP, Su MY, et al. Balloon-assisted enteroscopy with prophylactic polypectomy for Peutz-Jeghers syndrome: experience in Taiwan. *Dig Dis Sci* 2011; 56: 1472–1475.

22. Gorospe EC, Alexander JA, Bruining DH, et al. Performance of double-balloon enteroscopy for the management of small bowel polyps in hamartomatous polyposis syndromes. *J Gastroenterol Hepatol* 2013; 28: 268–273.

23. Serrano M, Mão-de-Ferro S, Pinho R, et al. Double-balloon enteroscopy in the management of patients with Peutz-Jeghers syndrome: a retrospective cohort multicenter study. *Rev Esp Enferm Dig* 2013; 105: 594–599.

24. Bizzarri B, Borrelli O, de’Angelis N, et al. Management of duodenal–jejunal polyps in children with Peutz-Jeghers syndrome with single-balloon enteroscopy. *J Pediatr Gastroenterol Nutr* 2014; 59: 49–53.

25. Torroni F. Conservative approach in Peutz-Jeghers syndrome: single-balloon enteroscopy and small bowel polypectomy. *World J Gastroenterol* 2014; 6: 318–323.

26. Kröner PT, Sancar A, Fry LC, et al. Endoscopic mucosal resection of jejunal polyps using double-balloon enteroscopy. *GE Port J Gastroenterol* 2015; 22: 137–142.

27. Belsha D, Urs A, Attard T, et al. Effectiveness of double-balloon enteroscopy-facilitated polypectomy in pediatric patients with Peutz-Jeghers syndrome. *J Pediatr Gastroenterol Nutr* 2017; 65: 500–502.

28. Blanco-Velasco G, Hernández-Mondragón OV, Blancas-Valencia JM, et al. Seguridad y eficacia...
de la polipectomía en intestino delgado utilizando enteroscopio asistido por balones en pacientes pediátricos con síndrome de Peutz-Jeghers. Rev Gastroenterol Mex 2018; 83: 234–237.

29. Wang Y, Bian D, Zhu H, et al. The role of double-balloon enteroscopy in reducing the maximum size of polyps in patients with Peutz-Jeghers syndrome: 12-year experience. J Dig Dis 2019; 20: 415–420.

30. Perrod G, Samaha E, Perez-Cuadrado-Robles E, et al. Small bowel polyp resection using device-assisted enteroscopy in Peutz-Jeghers syndrome: results of a specialised tertiary care centre. United European Gastroenterol J 2020; 8: 204–210.

31. Kirakosyan E and Lokhmatov M. High-tech diagnostic methods and enteroscopic treatment of children with Peutz-Jeghers syndrome. Eur J Pediatr Surg. Epub ahead of print 26 November 2019. DOI: 10.1055/s-0039-3400286.

32. Pennazio M, Venezia L, Cortegoso Valdivia P, et al. Device-assisted enteroscopy: an update on techniques, clinical indications and safety. Dig Liver Dis 2019; 51: 934–943.

33. Crockett SD, Wani S, Gardner TB, et al. American Gastroenterological Association Institute guideline on initial management of acute pancreatitis. Gastroenterology 2018; 154: 1096–1101.

34. Latchford AR, Neale K, Phillips RKS, et al. Peutz-Jeghers syndrome: intriguing suggestion of gastrointestinal cancer prevention from surveillance. Dis Colon Rectum 2011; 54: 1547–1551.

35. Möschler O, May A, Müller MK, et al. Complications in and performance of double-balloon enteroscopy (DBE): results from a large prospective DBE database in Germany. Endoscopy 2011; 43: 484–489.

36. Aretz S, Stienen D, Uhlhaas S, et al. High proportion of large genomic STK11 deletions in Peutz-Jeghers syndrome. Hum Mutat 2005; 26: 513–519.

37. Alhopuro P, Phichith D, Tuupanen S, et al. Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci USA 2008; 105: 5513–5518.